Annals of Surgical Oncology

, Volume 21, Issue 2, pp 539–546 | Cite as

Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites

  • Joji Kitayama
  • Hironori Ishigami
  • Hironori Yamaguchi
  • Hiroharu Yamashita
  • Shigenobu Emoto
  • Shoich Kaisaki
  • Toshiaki Watanabe
Gastrointestinal Oncology



Peritoneal metastasis of gastric cancer has extremely poor clinical outcomes. Recently, we developed a combination chemotherapy that used intraperitoneal (IP) paclitaxel (PTX) and produced excellent antitumor effects against peritoneal lesions. However, no information is available about the benefit of gastrectomy in cases with malignant ascites.


A total of 64 patients with severe peritoneal metastasis and ascites received IP PTX at 20 mg/m2 via implanted subcutaneous peritoneal access ports as well as intravenous (IV) PTX at 50 mg/m2 on days 1 and 8. S-1 was administered at 80 mg/m2 day for 14 consecutive days, followed by 7 days of rest. In all patients, investigative laparoscopy was performed around the combination chemotherapy, and gastrectomy was performed on patients who showed apparent shrinkage of their peritoneal nodules as well as negative peritoneal cytology at the second laparoscopy.


Gastrectomy was performed in 34 patients. The median course of chemotherapy before surgery was 5 courses (range 2–16). R0 operation was achieved in 22 patients (65 %), and grade 2 and 3 histological responses were obtained in 7 (21 %) and 1 (3 %) patient(s), respectively. The median survival time and 1-year overall survival of the gastrectomized patients were 26.4 months and 82 %, and those of the 30 patients who did not receive gastrectomy were 12.1 months and 26 %, respectively. Morbidity was minimal, and there was no mortality.


Salvage gastrectomy after chemotherapy of S-1 with IV and IP PTX is promising, even for patients with highly advanced gastric cancer and severe peritoneal metastasis and malignant ascites.


Gastric Cancer Median Survival Time Advanced Gastric Cancer Peritoneal Metastasis Peritoneal Dissemination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan and a Grant from the Ministry of Health and Welfare of Japan.


  1. 1.
    Ajani JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! J Clin Oncol. 2006;24:5473–4; author reply 5474–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.PubMedCrossRefGoogle Scholar
  6. 6.
    Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, et al. Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol. 2004;34:316–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol. 2007;37:930–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, et al. Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). In 2009 ASCO Annual Meeting. 2009; suppl; abstr 4545.Google Scholar
  9. 9.
    Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, et al. 2004 Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 8:454–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Strohlein MA, Bulian DR, Heiss MM. Clinical efficacy of cytoreductive surgery and hyperthermic chemotherapy in peritoneal carcinomatosis from gastric cancer. Expert Rev Anticancer Ther. 2011;11:1505–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575–81.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36:1131–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P’eng FK, et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer. 1996;77:14–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76:311–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology. 2010;78:40–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Japanese Gastric Cancer Assoc. Japanese Classification of Gastric Carcinoma—2nd English Edition. Gastric Cancer. 1998;1:10–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K, et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87:353–7.PubMedCrossRefGoogle Scholar
  21. 21.
    D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49:3380–4.PubMedGoogle Scholar
  23. 23.
    Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther. 1999;290:871–80.PubMedGoogle Scholar
  24. 24.
    Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res. 2007;13:2804–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Asakage M, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Yamada J, et al. Sulforaphane induces inhibition of human umbilical vein endothelial cells proliferation by apoptosis. Angiogenesis. 2006;9:83–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102:200–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009;100:311–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.PubMedCrossRefGoogle Scholar
  29. 29.
    Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep. 2009;11:200–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009;16:2385–90.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Joji Kitayama
    • 1
  • Hironori Ishigami
    • 1
  • Hironori Yamaguchi
    • 1
  • Hiroharu Yamashita
    • 1
  • Shigenobu Emoto
    • 1
  • Shoich Kaisaki
    • 1
  • Toshiaki Watanabe
    • 1
  1. 1.Department of Surgical OncologyUniversity of TokyoTokyoJapan

Personalised recommendations